Colin Michael Bond
CIK: 0002117233
Transaction Breakdown
Open Market Buys (P)0
High conviction signal
Open Market Sales (S)0
Position reduction
Option Exercises (M)0
Derivative conversions
Awards (A)0
Compensation grants
Other (G, F, J, C, D, …)0
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
AGMB
Agomab Therapeutics NV
Director
Discretionary Trading P&L
Holdings
Transaction History (0 total)
1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024.
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| 1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024. | ||||||
0-0 of 0 transactions
About Bond Colin Michael
Bond Colin Michael (SEC CIK 0002117233) files insider reports with the SEC as Director of Agomab Therapeutics NV (AGMB).
Signal8 holds 1 ownership filing by Bond Colin Michael, a Form 3, filed on Mar 18, 2026. A Form 3 is an initial statement of ownership: it reports holdings, not trades, so no Form 4 or Form 5 transactions are on record since Sep 2024.
The business address on Bond Colin Michael's filings is in ANTWERPEN.
Other insiders filing for Agomab Therapeutics NV (AGMB)
- Epstein David R, Director
- Kemula Pierre Thadee Victor, Chief Financial Officer
- Knotnerus Tim Jasper, Chief Executive Officer
- Garcia Marino, Director
- Patel Naimish, Director
- Hammer Ohad, Director